Norvir Federal Grants Were Roughly 1% Of Development Costs, Abbott Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Abbott's spending on Norvir R&D surpassed $300 mil., Chief Operating Office Jeffrey Leiden, MD/PhD, said
You may also be interested in...
Norvir Exclusivity Is Safe; NIH Says "March-In" Test Is Availability, Not Price
Abbott has met the requirements of the Bayh/Dole Act, NIH declares. "March-in" rights are not the right way to address drug pricing, agency says: that is up to Congress.
Norvir Exclusivity Is Safe; NIH Says "March-In" Test Is Availability, Not Price
Abbott has met the requirements of the Bayh/Dole Act, NIH declares. "March-in" rights are not the right way to address drug pricing, agency says: that is up to Congress.
Abbott Norvir Compulsory Licensing Would Take Several Years, NIH Says
NIH cannot grant Norvir patent licenses under the Bayh/Dole Act until Abbott has exhausted its appeals process, and follow-on products would have to gain standard FDA approval, the agency says. NIH expects to make a decision on whether to apply its "march-in" authority for the HIV product as soon as possible. The precedent established could have an immediate effect; NIH received a petition requesting the use of march-in rights for Pfizer's Xalatan.